Compare Ovoca Bio Plc with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
131.88%
0%
131.88%
6 Months
131.88%
0%
131.88%
1 Year
90.48%
0%
90.48%
2 Years
196.3%
0%
196.3%
3 Years
-55.56%
0%
-55.56%
4 Years
-79.08%
0%
-79.08%
5 Years
-73.33%
0%
-73.33%
Ovoca Bio Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
9.60%
EBIT to Interest (avg)
-2.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.31
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
14.35%
Valuation key factors
Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
2.38
EV to EBIT
-1.28
EV to EBITDA
-1.28
EV to Capital Employed
-1.28
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
5.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.60
-1.40
57.14%
Interest
0.00
0.00
Exceptional Items
0.00
-3.70
100.00%
Consolidate Net Profit
-0.00
-4.40
100.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 100.00% vs 8.33% in Dec 2023
About Ovoca Bio Plc 
Ovoca Bio Plc
Pharmaceuticals & Biotechnology
Ovoca Bio plc (Ovoca) is an Ireland-based biopharmaceutical company. The Company is focused on identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD).
Company Coordinates 
Company Details
Dublin 2, 17 Pembroke Street Upper , DUBLIN None : D02 AT22
Registrar Details






